AbbVie and Genmab Drug Combo Cuts DLBCL Progression Risk by 51%
A Phase 3 trial shows epcoritamab plus R-CHOP slashed disease progression or death risk by half in newly diagnosed blood cancer patients.
If you or someone you know has ever dealt with a blood cancer diagnosis, you know how much a treatment breakthrough can mean. AbbVie and Genmab just delivered one worth paying attention to: their drug epcoritamab, when paired with the standard chemotherapy regimen R-CHOP, cut the risk of disease progression or death by 51% in patients newly diagnosed with diffuse large B-cell lymphoma, or DLBCL for short.
DLBCL is the most common type of aggressive non-Hodgkin lymphoma, and finding something that meaningfully beats the existing standard of care is no small feat. R-CHOP — a cocktail of chemotherapy drugs — has been the go-to first-line treatment for years, so layering epcoritamab on top and seeing that kind of improvement in progression-free survival is genuinely significant news for oncology.
Read more Bitcoin Stuck Below $87,334 as Bulls and Bears Battle Key Levels →
What makes this even more notable is the mechanism behind epcoritamab. It's a bispecific antibody, meaning it's engineered to grab onto two different targets at once — essentially acting as a bridge that helps your immune system zero in on cancer cells. According to the companies, this is the first Phase 3 trial of a bispecific antibody combination to hit this kind of milestone in newly diagnosed DLBCL patients. That's a genuine first, not just marketing spin.
The results come from the Phase 3 EPCORE DLBCL-2 trial, and AbbVie and Genmab say they're already moving to engage regulatory authorities around the world to discuss next steps. Translation: they're pushing toward potential approval, though the timeline for that process will depend on regulators in each market. Investors in both companies will likely be watching those conversations closely.
For patients, the hope is that epcoritamab plus R-CHOP could eventually become a new standard of care — offering a more effective first strike against a cancer that, when it comes back, can be very hard to treat. Continue reading at Investing News Network.
